GlassScriptPhysician profile
Htoo Kyaw
NPI 1669873949
$37,589.57
in general payments reported to CMS, 2019-2025
35 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $1,514 · 2021: $29K · 2022: $3,225 · 2023: $1,792 · 2024: $817 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.55 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26,806.44 | 2020-2023 | Jeti |
| Cardiovascular Systems INC. | $1,233.61 | 2020-2022 | |
| Shockwave Medical, INC | $1,220.11 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $1,122.60 | 2019-2024 | |
| Amgen INC. | $970.94 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $712.07 | 2019-2024 | Wainua, Farxiga |
| Pfizer INC. | $613.04 | 2020-2025 | |
| Abiomed | $572.33 | 2023-2024 | Impella |
| Merck Sharp & Dohme LLC | $520.52 | 2022-2025 | Verquvo |
| Terumo Medical Corporation | $513.32 | 2020-2022 | |
| Medtronic, INC. | $503.07 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $467.52 | 2019-2025 | Eliquis |
| Bard Peripheral Vascular, INC. | $341.17 | 2021-2022 | |
| Biotronik INC. | $227.39 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.89 | 2022-2024 | Lifevest |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $202.22 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Irhythm Technologies, INC. | $194.44 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Chiesi USA, INC. | $162.38 | 2021-2022 | |
| Novo Nordisk INC | $149.46 | 2023-2024 | Wegovy |
| Philips North America LLC | $147.38 | 2020-2022 | |
| Medtronic Vascular, INC. | $123.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.84 | 2025 | |
| Cordis US Corp. | $62.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $55.42 | 2025 | Amvuttra |
| Penumbra, INC. | $48.50 | 2021 | |
| Cardiva Medical, INC. | $48.39 | 2023 | Cardiva Vascade 5f Vcs |
| Esperion Therapeutics, INC. | $48.20 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.78 | 2023 | Jardiance |
| Cvrx, INC. | $31.59 | 2025 | Barostim Neo System |
| Biosense Webster, INC. | $28.76 | 2023 | Nuvision Ice Catheter |
| Cardinal Health 200 LLC | $28.06 | 2020 | |
| Inspire Medical Systems, INC. | $24.60 | 2024 | Inspire |
| Teleflex LLC | $21.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.59 | 2024 | Dojolvi |
| Bayer Healthcare Pharmaceuticals INC. | $19.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Htoo Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.